Jpmorgan Chase & CO Phio Pharmaceuticals Corp. Transaction History

Jpmorgan Chase & CO

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 13, 2023	SELL	$0.33 - $0.58 $270 - $475	-820 Reduced 94.25%	50 $0
Q2 2022 Aug 11, 2022	SELL	$0.64 - $2.35 $401 - $1,473	-627 Reduced 41.88%	870 $1,000
Q1 2022 May 11, 2022	BUY	$0.73 - $1.1 $819 - $1,235	1,123 Added 300.27%	1,497 $1,000
Q4 2021 Feb 10, 2022	SELL	$0.99 - $1.99 $376 - $756	-380 Reduced 50.4%	374 $0
Q3 2021 Nov 12, 2021	BUY	$1.62 - $2.28 $1,221 - $1,719	754 New	754 $2,000

Ticker PHIO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 13,658,700
Market Cap $9.42M
Description
Phio Pharmaceuticals Corp. develops immuno-oncology therapeutics in the United States. It offers INTASYL therapeutic platform focuses on targeting tumor and immune cells by regulating genes of the immune system. The company develops PH-762 that activates immune cells to recognize and kill cancer cells by reducing the expression of the checkpoint...

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

Stay updated on Jpmorgan Chase & CO with notifications on news.